ERBB2 and breast carcinoma: The RESPECT (Randomized controlled trial of trastuzumab monotherapy versus trastuzumab plus chemotherapy in older patients with HER2-positive breast cancer) study, a prospective cohort study conducted alongside a randomized trial, provided important evidence supporting this approach [7].